What Invaio Sciences does

Invaio Sciences is a privately held agricultural biotechnology company founded in 2018 by Flagship Pioneering and headquartered in Cambridge, Massachusetts, with operations across six offices in the US, Brazil, Spain, Switzerland, and Italy. The company develops nature-positive crop protection technologies built around an AI-driven peptide discovery engine (Biologicals by Design™) and three proprietary delivery platforms — Trecise™ precision vascular infusion for trees, Microbe-Derived Particles (MDPs), and Nature-derived Lipid nanoParticles (NLPs) — that together are positioned as a vertically integrated stack for designing, protecting, and delivering bioactives into plants. Its commercial focus is anchored on citrus greening (HLB), where it obtained the first-ever regulatory registration for a Trecise™-based HLB solution in August 2023, and on adjacent opportunities in vegetables (e.g., diamondback moth) and row crops (e.g., corn rootworm); the December 2023 acquisition of Peptyde Bio added a defensin-based antimicrobial peptide pipeline.

Invaio pursues an enterprise B2B go-to-market that targets global agribusinesses and supply-chain leaders rather than individual growers, with named partners including Fundecitrus, Louis Dreyfus Company, and The Coca-Cola Company ("Save the Orange" initiative). Revenue mechanics are not publicly disclosed, but the model blends negotiated multi-year contracts routed through regional specialist sales teams with strategic co-development partnerships, future manufacturing collaborations (most notably with Ginkgo Bioworks for fermentation scale-up, announced February 2026), and downstream licensing potential. The company has raised over $142 million since inception — including an $88.9 million Series C led by Flagship Pioneering in May 2021 and $50 million in debt financing from K2 HealthVentures in October 2021 — and currently employs around 90 people of 22 nationalities.

The business is led by CEO and Board Director Amy O'Shea (appointed April 2024), with a leadership team that includes President/CCO Peleg Chevion, CCO Chris Judd, CFO Scott Kantor, and CSO Magalie Guilhabert, supported by a Scientific Advisory Board chaired by HHMI/NAS investigator Steve Jacobsen and including Nobel laureate Randy Schekman. Board representation spans PepsiCo (Pietro Tataranni), Ginkgo Bioworks (Ena Cratsenburg), and Novartis AI (Iya Khalil), providing direct cross-sector leverage into nutrition, synthetic biology, and AI/ML commercialization channels that complement the company's enterprise distribution strategy.

Name

Invaio Sciences

Legal name

Invaio Sciences, Inc.

Website

https://invaio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Invaio Sciences is an agricultural biotechnology company that uses an AI-driven peptide discovery engine and proprietary delivery platforms (Trecise™, MDPs, NLPs) to develop nature-positive crop protection solutions for citrus, vegetable, and row crop growers, sold via enterprise partnerships with global agribusinesses and supply-chain leaders.

Ownership category

akta.pro rank

Product category

Agricultural biotechnology — biological crop protection

NAICS

Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing (3253), Pesticide and Other Agricultural Chemical Manufacturing (32532), Pesticide and Other Agricultural Chemical Manufacturing (325320)

SIC

Agricultural Chemicals (2870), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologicals Distribution & Field Application Services (AFABAEAN)

akta.pro secondary industries

Biological Seed Treatments & Inoculants (within Biologicals) (AFABAEAL), Organic Adjuvants & Spray Aids (OMRI Surfactants, Stickers, Oils) (AFABAKAL)

Keywords

• Biological crop protection
• Agricultural biotechnology
• Peptide discovery
• Precision delivery
• Sustainable agriculture

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Commercial product sales (pre-launch / transition phase): Series C press release (May 25, 2021) explicitly states Invaio is using funds 'to expand its sustainable agriculture technology platforms' and 'transition from R&D to a fully commercial enterprise focused on eco-friendly farming methods,' indicating product sales to growers and agribusiness customers are the intended primary revenue model as Invaio Citrus Health™ and Trecise™-based products launch. No specific pricing or revenue figures are disclosed.
2. Strategic co-development and partnership-derived revenue: Revenue is also generated via strategic partnerships where Invaio supplies its Trecise™ / Biologicals by Design™ platforms to partners (e.g., Fundecitrus, Louis Dreyfus, The Coca-Cola Company, Ginkgo Bioworks) for joint development of HLB and crop protection solutions; the company describes preparing 'to launch our first HLB solution in Brazil.'
3. Future licensing / manufacturing collaboration (with Ginkgo Bioworks): The February 2026 collaboration with Ginkgo Bioworks covers microbial strain engineering and fermentation scale-up for Invaio's peptide-based crop protection inputs, positioning Invaio for grower-friendly commercial-scale production and downstream licensing/royalty potential.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels9 records

Core offering

Invaio Sciences develops and sells biological crop-protection solutions built on an AI-driven antimicrobial peptide discovery engine (Biologicals by Design™) paired with proprietary precision delivery platforms (Trecise™ tree infusion, Microbe-Derived Particles and Nature-derived Lipid nanoParticles). Its packaged solution lines target citrus greening (HLB) via Invaio Citrus Health™, vegetable pests and row-crop insects, and are sold primarily through enterprise partnerships with global agribusinesses and supply-chain leaders rather than direct-to-grower retail.

Product overview

Invaio Sciences offers a platform-plus-modules architecture for nature-positive agriculture. The core engine is the Biologicals by Design™ AI-driven peptide discovery platform, which is paired with three proprietary delivery platforms — Trecise™ (precision tree infusion), Nature-derived Lipid nanoParticles (NLPs), and Microbe-Derived Particles (MDPs) — that protect and deliver bioactives into crops. These platforms are packaged into solution lines targeting Tree Health (including Invaio Citrus Health™ for HLB/citrus greening), Vegetable Health, and Row Crop Health, with the Peptyde Bio antimicrobial peptide portfolio integrated after the December 2023 acquisition to bolster the fungicide and broader peptide pipeline.

Differentiator

Problem solved

Functional benefit

Brands

• Biologicals by Design™: Proprietary AI- and machine-learning-powered discovery platform for designing nature-informed peptides for crop protection.
• Trecise™
• Invaio Citrus Health™

Products and services

• Invaio Citrus Health™ Invaio's first citrus-focused solution targeting Huanglongbing (HLB/citrus greening); combines Trecise™ precision tree-infusion delivery with peptide-based bioactives and is suitable for use even on young trees. Targeted at Florida and Brazilian citrus growers.
• Tree Health Solutions Solution line covering perennial crop trees (including citrus and other tree crops) using Trecise™ delivery to protect tree health from pests and disease while reducing pesticide, water and nutrient inputs.
• Vegetable Health Solutions Targeted bioactives and delivery systems aimed at controlling pests in vegetable crops, including MDP-encapsulated peptides and proteins targeting diamondback moth and other resistant insect pests; demonstrated 2–5× performance vs. commercial biological benchmark in cabbage, kale, broccoli and cauliflower trials.
• Row Crop Health Solutions Approaches for row crops including corn rootworm control, leveraging peptide and RNA-based actives delivered via MDP and NLP platforms to address insecticide-resistant populations in corn and other row crops.
• Biologicals by Design™ platform AI-driven peptide discovery and design platform that uses generative AI, deep machine learning, structure-guided design, and genome mining for antimicrobial peptides to generate programmable, nature-derived active ingredients targeting specific pests and diseases with novel modes of action. Reported as 10x more efficient than traditional chemical discovery methods at identifying novel crop-health solutions. Sold/licensed to enterprise partners as part of co-development engagements.
• Trecise™ precision infusion delivery system Proprietary precision infusion/tree-injection delivery technology that places active ingredients directly into the vascular system of trees, dramatically reducing chemical spray needs. Deployed commercially as the delivery backbone for Invaio Citrus Health™ against HLB and described as the first major innovation around targeted delivery in crop protection in 25 years.
• Peptyde Bio antimicrobial peptide platform (acquired pipeline) Antimicrobial peptide discovery, design and characterization platform acquired by Invaio from Peptyde Bio in December 2023. Brings peptide candidates that complement or replace traditional chemical fungicides and integrates with Invaio's Biologicals by Design™ platform; focused initially on defensin-class AMPs for Botrytis cinerea, Fusarium spp., Septoria blotch, Asian soybean rust and certain oomycetes.

Quantifiable outcome

• Biologicals by Design™ platform is 10x more efficient than traditional chemical discovery methods at identifying novel crop health solutions
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered flagship, core and minor.

• Ginkgo BioworksflagshipTechnology or Integration · 18 February 2026Collaboration announced February 18, 2026, in which Ginkgo Bioworks and Invaio Sciences will develop manufacturing technology for peptide-based crop protection products. Ginkgo will leverage its engineered microbial strains and fermentation processes to help Invaio scale production of peptides at grower-friendly costs, addressing increasing pest resistance to conventional agricultural chemistry.
• FundecitrusflagshipStrategic or Co-development Partner · 13 January 2026Strategic collaboration announced January 13, 2025 (press release dated Jan 13, 2026) between Invaio Sciences and Fundecitrus (Fund for Citrus Protection, Araraquara, Brazil) to accelerate evaluation of peptide-based biological solutions against citrus greening (HLB). Fundecitrus provides specialized assays and field-based methods because CLas cannot be cultured in vitro; Invaio deploys its Trecise™ precision delivery platform to test candidates directly into citrus trees. Quotes from Ricardo Miranda (VP, Head of Global Development) and Avram Slovic (Head of LatAm).
• The Coca-Cola CompanyflagshipGTM or Marketing Partner · 5 September 2025Press release dated September 5, 2025: 'Invaio Sciences Joins Forces with The Coca-Cola Company to Save the Orange.' Invaio participates in the Save the Orange initiative with Coca-Cola and Fundecitrus, supporting the citrus supply chain's adoption of biological HLB solutions and bringing nature-positive crop protection to global beverage supply.
• Louis Dreyfus CompanycoreStrategic or Co-development Partner · 29 January 2024Press release dated January 29, 2024: 'Invaio Sciences and Louis Dreyfus Company Collaborate on Sustainable Citrus Groves for the Future.' The collaboration brings together Invaio's biological technologies and Louis Dreyfus' position as a major player in the global citrus supply chain to advance sustainable citrus production.
• Peptyde BioflagshipStrategic or Co-development Partner · 7 December 2023On December 7, 2023, Invaio Sciences acquired Peptyde Bio, a company specializing in antimicrobial peptide technology for agriculture. The acquisition integrates Peptyde's portfolio of peptide candidates (defensins targeting Botrytis cinerea, Fusarium spp., Septoria blotch, Asian soybean rust, certain oomycetes) into Invaio's AI-driven Biologicals by Design™ discovery platform, accelerating sustainable crop protection solutions. The deal is believed to be the first exit for a Danforth Technology Company.
• UCLA (Dr. Steve Jacobsen) — Scientific Advisory BoardflagshipOthers · 3 February 2021Dr. Steve Jacobsen, Professor of Molecular Cell and Developmental Biology and Biological Chemistry at UCLA and Howard Hughes Medical Institute Investigator (elected to NAS in 2011), chairs Invaio's Scientific Advisory Board. He contributed to building the SAB and recruiting R&D talent, and is also a scientific co-founder of Inari Agriculture (a Flagship Pioneering company).
• UC Berkeley (Dr. Randy Schekman) — Scientific Advisory BoardcoreOthers · 3 February 2021Dr. Randy Schekman, Professor in the Department of Molecular and Cell Biology at the University of California, Berkeley, and HHMI investigator, joined the Invaio SAB. Schekman received the 2013 Nobel Prize in Medicine or Physiology for vesicle trafficking and joined to develop insights into harnessing vesicles to deliver biological molecules to plants.
• NC State University (Dr. Rodolphe Barrangou) — Scientific Advisory BoardcoreOthers · 3 February 2021Dr. Rodolphe Barrangou, Distinguished Professor at NC State University (NAS, NAE, NAI and American Academy of Microbiology), joined the Invaio SAB. He brings experience commercializing CRISPR-related technologies and phage-host interaction science.
• PepsiCo (Dr. Pietro Antonio Tataranni)minorStrategic or Co-development Partner · 18 November 2020On November 18, 2020, Invaio announced the appointment of Dr. Pietro Antonio Tataranni (Chief Medical Officer and Senior VP, R&D Life Sciences at PepsiCo) to its Board of Directors to contribute nutrition and bio-sciences expertise to Invaio's mission. PepsiCo itself is a board-affiliation partner rather than an operating commercial partner.
• Ginkgo Bioworks (Ena Cratsenburg)minorStrategic or Co-development Partner · 18 November 2020Ena Cratsenburg, Chief Business Officer at Ginkgo Bioworks, joined Invaio's Board of Directors on November 18, 2020. This board relationship predated and supported the Feb 2026 manufacturing collaboration; Cratsenburg brings synthetic-biology and commercialization expertise.
• Novartis AI Innovation Center (Dr. Iya Khalil)minorStrategic or Co-development Partner · 18 November 2020Dr. Iya Khalil, Global Head of the AI Innovation Center at Novartis (Novartis-Microsoft collaboration), joined Invaio's Board of Directors on November 18, 2020. Khalil is a co-founder of GNS Healthcare and brings AI / machine-learning expertise to support Invaio's discovery platforms.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Indigo Agriculture: Fellow Flagship Pioneering ag-biotech company developing microbial seed treatments and plant microbiome solutions. Directly comparable as a privately held, biology-based crop-inputs company backed by the same VC and pursuing nature-positive replacements for synthetic chemistries — Indigo also shares board overlap (Robert Berendes is Chairman of both Indigo and Invaio).
• Inari Agriculture: Flagship Pioneering ag-biotech applying predictive design and multiplex gene editing to seeds; co-founded by Ignacio Martinez (Invaio's founding CEO) with Steve Jacobsen (Invaio SAB Chair) as scientific co-founder. Closest Flagship-sibling competitor in applying computational biology to plant/crop inputs.
• AgBiome: Ag-biotech company using a proprietary microbial GENESIS™ discovery platform to identify biological crop-protection products (e.g., Howler and Theia fungicides). Closely comparable technology stack (biology discovery platform → commercial biocontrol products) targeting the same growers and same chemical-replacement thesis.
• Pivot Bio: Microbial nitrogen-fixation company selling in-furrow and foliar biological products to row-crop growers as a replacement for synthetic nitrogen fertilizer. Same broad thesis (microbes replace synthetic chemistry), same customer type (large-scale growers), and similar scale-up-from-R&D-to-commercial trajectory.

Emerging players

• BioConsortia: Ag-biotech developing microbial consortia products for nitrogen fixation, phosphorus solubilization, and biocontrol. Comparable discovery-then-product model and row-crop/specialty-crop overlap, though smaller and earlier-stage than Invaio.
• Sound Agriculture: Ag-biotech offering microbe-based SOURCE™ nitrogen-fixation and EFFICIENCY™ bio-inspired chemistry products to row-crop growers. Comparable in offering nature-positive biological crop inputs that reduce synthetic fertilizer use; smaller scale and narrower product set than Invaio.

Others

• Ginkgo Bioworks: Synthetic biology platform / cell-programming company that is also Invaio's manufacturing partner (Feb 2026 collaboration) and has a board representative (Ena Cratsenburg) on Invaio's board. Comparable in AI-driven biological design and biological manufacturing, but serves many end-markets beyond agriculture.

Broad incumbents

• Syngenta (Syngenta Group): Global crop-protection incumbent (now part of Syngenta Group / Sinochem) offering chemical pesticides, seeds, and digital agronomy. Provides the synthetic chemistry baseline that Invaio's biologicals aim to replace; relevant as the dominant competitor Invaio must displace in growers' spray regimes.
• Bayer Crop Science: Division of Bayer operating one of the world's largest crop-protection and seed franchises, with growing investment in biologics. Sets the competitive context for any nature-positive crop input alternative and is a benchmark for distribution scale.
• Corteva Agriscience: Global crop-protection and seed major spun out of DowDuPont; offers chemical and biological inputs across row and specialty crops. Comparable broad incumbent that biologicals companies like Invaio must compete against on grower relationships and shelf-space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/invaio
• Facebookfacebook.com/invaio
• LinkedInlinkedin.com/company/invaio

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries5 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Invaio Sciences